Roche's experimental obesity shot enicepatide reduced blood sugar and body weight by 15.5% in type-2 diabetes patients in a mid-stage trial, with a meaningful proportion reaching normalized glucose levels within less than a year of treatment.
Amylyx Pharmaceuticals' experimental drug avexitide met its primary endpoint in a Phase 3 trial for post-bariatric hypoglycemia, showing a 55% reduction in serious low blood sugar events compared to placebo in patients who experienced dangerously low blood sugar following weight-loss surgery.
A major clinical trial found that real-time continuous glucose monitoring (CGM) significantly improves blood glucose management in adults with type 2 diabetes treated with basal insulin, offering evidence for expanded use of the technology beyond type 1 diabetes.
New research reveals that approximately 10% of people carry specific genetic variants that make popular diabetes and weight-loss drugs like Ozempic and Wegovy significantly less effective, providing the first genetic explanation for variable drug response.
